Predict your next investment

NeuroVigil company logo
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment

See what CB Insights has to offer


Series A | Alive

Total Raised


About NeuroVigil

NeuroVigil is a world leader in neurotechnology and computational neuroscience, and is dedicated to the betterment of the human condition by merging non-invasive wireless brain recording technology with advanced computational analysis techniques applied exclusively on human data. The company has developed proprietary technology which leverages the dynamic oscillations produced across the sleep/wake cycle in order to systematically scan the human brain for signs of pathologic activity, years in advance of cognitive or behavioral symptoms.

NeuroVigil Headquarter Location

1258 Prospect Street

La Jolla, California, 92037,

United States

Latest NeuroVigil News

Canada Joins Philip Low's NeuroVigil Conglomerate

Dec 6, 2020

Last updated Dec 4, 2020 Silicon Valley-based neurotech intellectual property powerhouse NeuroVigil, and the University of Waterloo, Silicon Valley’s largest international supplier of tech talent, announced today they have signed an agreement clearing the way for University of Waterloo’s formal membership in NeuroVigil’s conglomerate, headed by Philip Low, NeuroVigil’s Chairman, CEO and Founder. The signing marks the formal international launch of Dr. Low’s vision to build a network of universities, healthcare systems and companies dedicated to the development of a host of sustainable biotechnologies, without imposing any cost on non-human animals, consistent with the 2012 Cambridge Declaration on Consciousness, the first formal document recognizing that consciousness was not limited to human animals. This press release features multimedia. View the full release here: Dr. Philip Low NeuroVigil Chairman, CEO & Founder (Photo: Business Wire) “When I hosted the Francis Crick Memorial Conference in Cambridge, I invited distinguished colleagues to propose minor edits to the Cambridge Declaration on Consciousness which I had written and to boldly put their reputation on the line and join me in signing it. They heeded the call and that moment has changed history and laws all over the world and has led to more scientists and technologists putting their genius at the service of people without harming the environment, rather than playing a zero-sum game with it. I have taken the same community-focused approach with the conglomerate, in many ways one of the Declaration’s technological embodiments, and am delighted to choose as the first international invitee of my consortium a university renowned for its boldness, for its brilliance, and for its sense of community, demonstrated each day and night in the quality of its students, staff, leaders, alumni and spinoffs. This is a proud moment for Innovation, for those who depend on it, for Entrepreneurship, for the Environment, and for Canada, and it too shall powerfully reverberate across space-time,” said Dr. Low. “I am grateful to University of Waterloo’s enlightened leadership and especially to Dr. David Fransen, on my business advisory board and my Head of Strategic Operations for Canada, for having suggested Waterloo, and for having been instrumental in making this partnership a reality.” “We are truly looking forward to working with Dr. Low and NeuroVigil on this initiative,” said Dr. Charmaine Dean, University of Waterloo’s Vice-President of Research. The conglomerate is focused on three main areas: 1. Communication and locomotion technologies for individuals suffering from ALS and Strokes, a project initiated by Dr. Low and the late Dr. Stephen Hawking; 2. Detection of biomarkers in asymptomatic individuals suffering from brain cancer or Parkinson’s; 3. Detection of drug side effects in seniors, as well as neurological damage heralding the onset of Alzheimer’s disease. The technologies are entirely human-based and non-invasive, and do not require animal testing of any kind. While all new companies in the conglomerate must have access to airtight intellectual property, an exception may be made for plant-based therapeutic companies which seek access to clinical trials to distinguish themselves in a crowded field. Conglomerate members provide intellectual …

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeuroVigil

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroVigil is included in 5 Expert Collections, including Neuroscience.



2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.


Internet of Things ( IoT )

3,149 items


Sleep Health & Wellness

795 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.


Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health & Wellness Assessment Tools

2,094 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes providers.

NeuroVigil Patents

NeuroVigil has filed 1 patent.

The 3 most popular patent topics include:

  • Electrodiagnosis
  • Electroencephalography
  • Electrophysiology
patents chart

Application Date

Grant Date


Related Topics



Electroencephalography, Neurophysiology, Electrodiagnosis, Electrophysiology, Neuroscience


Application Date


Grant Date


Related Topics

Electroencephalography, Neurophysiology, Electrodiagnosis, Electrophysiology, Neuroscience



NeuroVigil Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NeuroVigil Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.